In the last decade, the importance of the innate immune response in AD pathogenesis has risen, driven by the discovery of multiple variants in immune system‐associated genes conferring an increased risk for the development of sporadic AD, including the microglia cell surface receptors TREM2 and CD33 9, 10. The gene discussed is CD33; the disease is Alzheimer disease.